Military testosterone screening divides medical experts

The US Department of Defense’s decision to include testosterone screening in annual health assessments has triggered debate about the usefulness of broad hormone testing in a population context. The reporting shows reactions ranging from ‘promising’ to ‘crazy’. Younger service members under thirty can opt in voluntarily.

What is testosterone deficiency, exactly?

Testosterone declines gradually with age, in men by roughly one percent per year after age thirty. When this becomes a medical problem is contested. There is no universally accepted threshold. Symptoms such as fatigue, muscle loss, and reduced libido overlap heavily with other conditions and normal ageing.

Critics of broad screening point out that testosterone therapy is not without risk: increased likelihood of blood clots, sleep apnoea, and possible cardiovascular problems have been reported, particularly in men who do not have a clinical deficiency. Proponents argue that testosterone deficiency is underdiagnosed and that early intervention can improve performance and health outcomes.

Hormones and ageing: an unresolved debate

In the broader field of ageing science, age-related hormone decline is an active area of research. Whether restoring hormones to youthful levels is beneficial or carries risks remains far from settled. Large randomised controlled trials are largely absent.

The military context adds another layer: performance pressure could lead to testosterone therapy being used in men without a genuine deficiency. That is medically undesirable. How exactly the screening will be structured and which thresholds will be applied has not yet been published.

Read the original article